Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Bibliografiska uppgifter
Huvudupphovsmän: Black, S, Wilcock, G, Haworth, J, Hendrix, S, Zavitz, K, Christensen, D, Binger, M, Bass, S, Laughlin, M, Swabb, E
Materialtyp: Conference item
Publicerad: 2006

Liknande verk